These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1103 related articles for article (PubMed ID: 33095513)

  • 21. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis.
    Barochiner J; Martínez R
    J Clin Pharm Ther; 2020 Dec; 45(6):1244-1252. PubMed ID: 32767823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
    Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
    J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
    Ssentongo AE; Ssentongo P; Heilbrunn ES; Lekoubou A; Du P; Liao D; Oh JS; Chinchilli VM
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33154144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
    Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
    J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
    Choksi TT; Zhang H; Chen T; Malhotra N
    Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study.
    Shams E; Kamalumpundi V; Cheng L; Taiwo A; Shibli-Rahhal A; Dokun AO; Correia MLG
    Arq Bras Cardiol; 2023 Mar; 120(4):e20220277. PubMed ID: 37098985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
    PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
    Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
    BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis.
    Zhang X; Yu J; Pan LY; Jiang HY
    Pharmacol Res; 2020 Aug; 158():104927. PubMed ID: 32422341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
    Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
    Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
    Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
    Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis.
    Zhang G; Wu Y; Xu R; Du X
    J Med Virol; 2021 Apr; 93(4):2287-2300. PubMed ID: 33231299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies.
    Bavishi C; Whelton PK; Mancia G; Corrao G; Messerli FH
    J Hypertens; 2021 Apr; 39(4):784-794. PubMed ID: 33560054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.
    Kumar S; Nikravesh M; Chukwuemeka U; Randazzo M; Flores P; Choday P; Raja A; Aseri M; Shivang S; Chaudhuri S; Barve P
    Clin Cardiol; 2022 Jul; 45(7):759-766. PubMed ID: 35481554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension.
    Kuzeytemiz M; Tenekecioglu E
    J Investig Med; 2022 Mar; 70(3):786-791. PubMed ID: 34987107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study].
    Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B
    Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
    Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
    J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.